2024
Assessing Direct and Spillover Effects of Intervention Packages in Network-randomized Studies
Buchanan A, Hernández-Ramírez R, Lok J, Vermund S, Friedman S, Forastiere L, Spiegelman D. Assessing Direct and Spillover Effects of Intervention Packages in Network-randomized Studies. Epidemiology 2024, 35: 481-488. PMID: 38709023, DOI: 10.1097/ede.0000000000001742.Peer-Reviewed Original ResearchIntervention packageEffectiveness of interventional packageImprove intervention deliveryPeer education interventionHIV prevention trialsPeer educator trainingMarginal structural modelsPublic health impactHIV risk behaviorsIntervention deliveryIntervention NetworkEducational interventionParticipant visitsPrevention trialsFollow-up visitRisk behaviorsHealth impactsInterventionEducational trainingParticipantsSpillover effectsVisitsHIVExposed networksPeer
2020
Correction to: Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials
Brault MA, Spiegelman D, Abdool Karim SS, Vermund SH. Correction to: Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials. Current HIV/AIDS Reports 2020, 17: 577-577. PMID: 32601917, PMCID: PMC10714314, DOI: 10.1007/s11904-020-00513-2.Peer-Reviewed Original ResearchIntegrating and Interpreting Findings from the Latest Treatment as Prevention Trials
Brault MA, Spiegelman D, Abdool Karim SS, Vermund SH. Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials. Current HIV/AIDS Reports 2020, 17: 249-258. PMID: 32297219, PMCID: PMC7260110, DOI: 10.1007/s11904-020-00492-4.Peer-Reviewed Original Research
2019
Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence
Brault MA, Spiegelman D, Hargreaves J, Nash D, Vermund SH. Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82: s104-s112. PMID: 31658196, PMCID: PMC6820703, DOI: 10.1097/qai.0000000000002168.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHIV transmissionHIV plasma loadReducing HIV IncidenceHIV prevention trialsCommunity-level interventionsDeployable vaccineViral suppressionHIV testingHIV incidencePrevention trialsUninfected personsChronic conditionsHIV investmentsEarly treatmentTreat strategySexual partnersViral expressionTransmission riskHIVTrialsTreatmentInconsistent findingsPreventionSaharan Africa
2018
Assessing Individual and Disseminated Effects in Network-Randomized Studies
Buchanan AL, Vermund SH, Friedman SR, Spiegelman D. Assessing Individual and Disseminated Effects in Network-Randomized Studies. American Journal Of Epidemiology 2018, 187: 2449-2459. PMID: 30052722, PMCID: PMC6211234, DOI: 10.1093/aje/kwy149.Peer-Reviewed Original Research
2010
Rethinking Prevention of HIV Type 1 Infection
Burns DN, Dieffenbach CW, Vermund SH. Rethinking Prevention of HIV Type 1 Infection. Clinical Infectious Diseases 2010, 51: 725-731. PMID: 20707698, PMCID: PMC3071685, DOI: 10.1086/655889.Peer-Reviewed Original Research
2004
Tolerance and Safety of Different Concentrations of Chlorhexidine for Peripartum Vaginal and Infant Washes: HIVNET 025
Wilson CM, Gray G, Read JS, Mwatha A, Lala S, Johnson S, Violari A, Sibiya PM, Fleming TR, Koonce A, Vermund SH, McIntyre J. Tolerance and Safety of Different Concentrations of Chlorhexidine for Peripartum Vaginal and Infant Washes: HIVNET 025. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 35: 138-143. PMID: 14722445, PMCID: PMC2753236, DOI: 10.1097/00126334-200402010-00006.Peer-Reviewed Original ResearchConceptsChris Hani Baragwanath HospitalPrevention of motherHIV Type 1Solution of chlorhexidineConcentrations of chlorhexidineChild transmissionBaragwanath HospitalMaternal symptomsPrevention trialsThird trimesterClinical indicationsMaternity unitsSubjective complaintsVaginal areaWash groupType 1ChlorhexidineInfant examinationWomenSustainable interventionsTolerable concentrationInterventionMothersWashDifferent concentrations